(Q59567546)
Statements
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer (English)
Guy Jerusalem
Angelica Fasolo
Veronique Dieras
Jonas Bergh
Luc Vittori
Yufen Zhang
Cristian Massacesi
25 November 2010